What is Zacks Research’s Estimate for Omnicell Q2 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Omnicell in a research note issued on Thursday, March 5th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.19 per share for the quarter, down from their prior estimate of $0.20. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

Several other analysts have also commented on OMCL. Piper Sandler reiterated an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research report on Wednesday, January 7th. Wells Fargo & Company increased their price objective on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Benchmark upped their target price on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Finally, Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a report on Wednesday, February 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $54.50.

Omnicell Trading Down 2.2%

NASDAQ:OMCL opened at $41.30 on Monday. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. The stock has a fifty day moving average price of $44.60 and a two-hundred day moving average price of $38.35. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 1,032.76, a PEG ratio of 1.48 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. During the same quarter last year, the business posted $0.60 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its holdings in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after purchasing an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after buying an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Omnicell by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares in the last quarter. Jane Street Group LLC boosted its stake in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after acquiring an additional 109,382 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Omnicell during the 2nd quarter worth $282,000. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.